Azelastine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Azelastine Availability in 2026

As an allergist, ENT specialist, or primary care provider, you may be fielding patient questions about difficulty filling Azelastine prescriptions. This article provides a concise clinical overview of the current supply landscape, prescribing implications, and actionable strategies to help your patients maintain access to effective allergy treatment.

Current Supply Status

As of early 2026, Azelastine hydrochloride is not listed on the FDA Drug Shortage Database. There is no formal, nationwide shortage of any Azelastine formulation — including generic nasal spray, Astepro (OTC), Dymista, or generic ophthalmic solution.

However, providers should be aware that patients may encounter localized stock-outs, particularly during peak allergy seasons. These episodes are driven by demand surges rather than manufacturing or supply chain disruptions.

Timeline: Key Supply and Access Milestones

Understanding the recent history of Azelastine's availability helps contextualize patient inquiries:

• 1996: Astelin (Azelastine 0.1% nasal spray) receives FDA approval
• 2008: Generic Azelastine 0.1% nasal spray becomes available
• 2012: Dymista (Azelastine 137 mcg / Fluticasone 50 mcg) receives FDA approval
• 2022: Astepro (Azelastine 0.15%) transitions to OTC status — a significant access milestone
• 2023-2025: No FDA-listed shortages; multiple generic manufacturers maintain supply
• 2026: Supply remains stable across all formulations

The OTC transition of Astepro in 2022 was the most significant access change, effectively removing the prescription barrier for the 0.15% formulation. This has been a net positive for patient access but has created some prescribing and insurance coverage complexities.

Prescribing Implications

Formulary and Coverage Changes

Many insurance formularies have responded to Astepro's OTC transition by:

• Removing coverage for prescription Azelastine 0.15% (since the OTC equivalent is available)
• Maintaining coverage for Azelastine 0.1% (Astelin generics) as a prescription benefit
• Requiring step therapy for Dymista — patients must trial separate Azelastine and intranasal corticosteroid before the combination product is approved
• Increasing prior authorization requirements for brand Dymista

When prescribing Azelastine, consider specifying the formulation strength to avoid pharmacy-level confusion. If a patient's insurance no longer covers the 0.15% prescription, directing them to OTC Astepro may be the most practical solution.

Vasomotor Rhinitis Considerations

For patients with vasomotor (non-allergic) rhinitis, Azelastine remains a first-line intranasal option. This indication is prescription-only, and patients with this diagnosis may need documentation for insurance to cover prescription Azelastine even when the OTC version exists. Clear documentation of the vasomotor rhinitis diagnosis (ICD-10: J30.0) supports authorization requests.

Pediatric Prescribing

Age-based prescribing varies by formulation:

• Astepro OTC (0.15%): Labeled for ages 6+
• Astelin (0.1%): Ages 5+ for seasonal allergic rhinitis
• Dymista: Ages 6+
• Optivar ophthalmic: Ages 3+

Availability Picture

The current availability landscape for Azelastine in 2026:

Widely Available

• OTC Astepro 0.15%: Stocked at most major retailers and pharmacies; $15-$22 per bottle
• Generic Azelastine 0.1% nasal spray: Available at most pharmacies; $15-$45 with discount cards
• Generic Azelastine ophthalmic: Widely available; $15-$80

Potentially Limited

• Dymista: Not universally stocked due to higher cost ($180-$350); may need to be special-ordered. Some pharmacies carry it only on demand.

Multiple generic manufacturers (Apotex, Amneal, Sun Pharma, and others) supply Azelastine nasal spray, providing supply chain redundancy.

Cost and Access

Cost remains a relevant factor, especially for the Dymista formulation:

• Generic Azelastine: Affordable at $15-$45/month; minimal access barrier
• OTC Astepro: $15-$22; no prescription cost but also no insurance coverage
• Dymista: Significant cost without insurance ($180-$350); Viatris offers a copay card reducing cost to $0-$30/month for commercially insured patients

For uninsured patients needing Dymista, the Viatris Patient Assistance Program may provide the medication at no cost. Direct patients to viatris.com for eligibility details or to NeedyMeds.org for additional options.

For comprehensive pricing resources, see our patient-facing article on saving money on Azelastine, and our provider-specific guide on helping patients save on Azelastine.

Tools and Resources

When patients report difficulty finding Azelastine, consider these resources:

• Medfinder for Providers: Real-time pharmacy stock checking tool. Direct patients to Medfinder.com, or use the provider portal at medfinder.com/providers to check availability during the visit.
• FDA Drug Shortage Database: accessdata.fda.gov — confirm whether a formal shortage exists
• Discount card services: GoodRx, SingleCare, and RxSaver can reduce cash prices on generic Azelastine significantly
• Manufacturer resources: Dymista.com for copay cards; Viatris.com for patient assistance

Alternative Prescribing Options

When Azelastine is unavailable or unaffordable, evidence-based alternatives include:

• Olopatadine (Patanase): Intranasal antihistamine with similar efficacy; potentially better taste profile; prescription only
• Intranasal corticosteroids (Fluticasone, Mometasone): First-line for allergic rhinitis per guidelines; OTC options available; not equivalent for vasomotor rhinitis
• Combination approach: Prescribing separate Azelastine + Fluticasone nasal sprays can approximate Dymista at lower total cost
• Oral antihistamines (Cetirizine, Fexofenadine): Less effective for nasal symptoms than intranasal options but may suffice for mild cases

See our detailed comparison in the alternatives to Azelastine article.

Looking Ahead

The Azelastine supply outlook for 2026 and beyond is favorable:

• Multiple generic manufacturers ensure competitive pricing and supply redundancy
• OTC availability of Astepro provides a prescription-free access path
• No manufacturing or regulatory concerns are expected to affect supply
• Growing telehealth adoption makes prescribing more accessible for patients who need prescription formulations

The primary access challenge for patients is now more about navigating the prescription vs. OTC landscape and insurance coverage changes than actual drug availability.

Final Thoughts

Azelastine remains widely available in 2026 with no formal shortage. The main prescribing challenges involve insurance coverage shifts following the Astepro OTC transition and the higher cost of Dymista. By understanding the current formulary landscape and directing patients to appropriate resources — including Medfinder for Providers — you can help ensure your patients maintain access to effective allergy treatment.

For a practical guide on helping patients locate their medication, see our article on how to help patients find Azelastine in stock.